
A New Era in Alzheimer’s Diagnosis
On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, developed by Fujirebio Diagnostics. This marks the first FDA-cleared blood test designed to aid in diagnosing Alzheimer’s disease by detecting amyloid plaques in the brain. The test